Earnings call transcript: Ascendis Pharma Q4 2024 sees revenue rise
Ascendis Pharma (ASND) reported its fourth-quarter 2024 earnings, highlighting a significant revenue increase and a positive market reaction. The company posted total revenue of €173.9 million for the ...
BMJ20h
Forecasting cardiovascular disease risk and burden in China from 2020 to 2030: a simulation study based on a nationwide cohort
Background Cardiovascular disease (CVD) remains a significant public health challenge in China. This study aimed to project ...